Johnson & Johnson $JNJ Shares Purchased by Sandy Cove Advisors LLC

Sandy Cove Advisors LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 4.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,523 shares of the company’s stock after buying an additional 307 shares during the quarter. Sandy Cove Advisors LLC’s holdings in Johnson & Johnson were worth $996,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. MassMutual Private Wealth & Trust FSB grew its position in Johnson & Johnson by 0.5% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 205,088 shares of the company’s stock worth $31,327,000 after buying an additional 998 shares during the last quarter. Range Financial Group LLC grew its position in Johnson & Johnson by 4.8% in the second quarter. Range Financial Group LLC now owns 16,656 shares of the company’s stock worth $2,544,000 after buying an additional 770 shares during the last quarter. Little House Capital LLC grew its position in Johnson & Johnson by 46.3% during the 2nd quarter. Little House Capital LLC now owns 42,015 shares of the company’s stock worth $6,418,000 after purchasing an additional 13,304 shares in the last quarter. First National Corp MA ADV grew its position in Johnson & Johnson by 1.5% during the 2nd quarter. First National Corp MA ADV now owns 9,786 shares of the company’s stock worth $1,495,000 after purchasing an additional 142 shares in the last quarter. Finally, Everpar Advisors LLC grew its position in Johnson & Johnson by 4.3% during the 2nd quarter. Everpar Advisors LLC now owns 10,666 shares of the company’s stock worth $1,629,000 after purchasing an additional 442 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $177.49 on Tuesday. The firm’s 50-day moving average is $171.25 and its 200-day moving average is $161.36. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $181.16. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company has a market cap of $427.46 billion, a price-to-earnings ratio of 18.98, a PEG ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the previous year, the firm posted $2.82 EPS. The business’s revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson’s payout ratio is presently 55.61%.

Wall Street Analyst Weigh In

Several research firms have weighed in on JNJ. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday. UBS Group boosted their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a report on Thursday, July 17th. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Finally, Royal Bank Of Canada boosted their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $176.29.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.